Results 231 to 240 of about 33,582 (263)

THE RELATIONSHIP BETWEEN MYOSTATIN, INFLAMMATORY MARKERS AND SARCOPENIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

Journal of renal nutrition, 2022
OBJECTIVE To determine the prevalence of sarcopenia in patients with chronic kidney disease (CKD), investigate the relationship of the serum myostatin level with sarcopenia and inflammatory markers.
E. Yaşar, N. Tek, M. Y. Tekbudak, G. Yurtdaş, Ö. Gülbahar, Gizem Özata Uyar, Zeynep Ural, Ö. Çelik, Y. Erten   +8 more
semanticscholar   +1 more source

siRNAs targeting mouse myostatin

Biochemistry (Moscow), 2008
Eight different mouse myostatin small interfering RNA (siRNAs) were synthesized and tested. Five siRNAs showed a pronounced biological effect reducing myostatin mRNA content. For two of them, the myostatin mRNA level was reduced 3- and 4-fold, respectively.
V A, Furalyov, I V, Kravchenko, V P, Khotchenkov, V O, Popov   +3 more
openaire   +2 more sources

Myostatin and carbohydrate disturbances

Endocrine Research, 2016
Purpose/aim of the study: Myostatin is a myokine that has been shown to inhibit muscle growth and to have potentially deleterious effects on metabolism. The aim of the current study was to compare its circulating serum levels in subjects from the whole spectrum of carbohydrate disturbances leading to diabetes.A total of 159 age-, sex-, and BMI-matched ...
Yavor S, Assyov, Tsvetelina V, Velikova, Zdravko A, Kamenov   +2 more
openaire   +2 more sources

Muscle-derived myostatin is a major endocrine driver of follicle-stimulating hormone synthesis.

Science
Myostatin is a paracrine myokine that regulates muscle mass in a variety of species, including humans. In this work, we report a functional role for myostatin as an endocrine hormone that directly promotes pituitary follicle-stimulating hormone (FSH ...
Luisina Ongaro, Xiang Zhou, Ying Wang, Hailey Schultz, Ziyue Zhou, Evan R S Buddle, Emilie Brûlé, Yeu-Farn Lin, G. Schang, Adam Hagg, Roselyne Castonguay, Yewei Liu, G. H. Su, N. Seidah, Kevin C Ray, Seth J Karp, Ulrich Boehm, F. Ruf-zamojski, S. Sealfon, Kelly L Walton, Se-jin Lee, Daniel J. Bernard   +21 more
semanticscholar   +1 more source

Effects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice.

Biomaterials, 2020
Duchenne muscular dystrophy (DMD) is a devastating disorder caused by loss of functional dystrophin protein, resulting in muscle wasting. Enhancing muscle growth by inhibiting myostatin, a growth factor negatively regulating skeletal muscle mass, is a ...
Ning Ran, Xianjun Gao, Xue Dong, Junjin Li, Caorui Lin, Mengyuan Geng, HaiFang Yin   +6 more
semanticscholar   +1 more source

Myostatin in combination with creatine phosphokinase or albumin may differentiate patients with cirrhosis and sarcopenia.

American Journal of Physiology - Gastrointestinal and Liver Physiology, 2021
BACKGROUND/OBJECTIVES In patients with liver cirrhosis (LC), sarcopenia is correlated with frequent complications and increased mortality. Myostatin-a myokine-is a potential biomarker of skeletal mass and/or sarcopenia.
Theodoros Alexopoulos, L. Vasilieva, M. Kontogianni, R. Tenta, A. Georgiou, E. Stroumpouli, I. Mani, A. Alexopoulou   +7 more
semanticscholar   +1 more source

Myostatin and muscle atrophy during chronic kidney disease.

Nephrology, Dialysis and Transplantation, 2020
Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1/Akt (IGF-1/Akt ...
Stanislas Bataille, P. Chauveau, D. Fouque, M. Aparicio, L. Koppe   +4 more
semanticscholar   +1 more source

Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma

Hepatology Research, 2021
In patients with liver cirrhosis, high levels of serum myostatin are associated with poor prognosis. We aimed to clarify the influence of myostatin on the prognosis of patients with non‐alcoholic fatty liver disease–hepatocellular carcinoma (NAFLD‐HCC ...
Sachiyo Yoshio, Tomonari Shimagaki, R. Hashida, T. Kawaguchi, Y. Tsutsui, Y. Sakamoto, Y. Yoshida, Hironari Kawai, Shiori Yoshikawa, Taiji Yamazoe, Taizo Mori, Y. Osawa, S. Itoh, M. Fukai, T. Yoshizumi, A. Taketomi, M. Mori, T. Kanto   +17 more
semanticscholar   +1 more source

Myostatin: Biology and Clinical Relevance

Mini-Reviews in Medicinal Chemistry, 2006
Myostatin is a negative regulator of muscle mass. Important advances in our understanding of the complex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Here we present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Carnac, Gilles, Ricaud, Stéphanie, Vernus, Barbara, Bonnieu, Anne   +3 more
openaire   +2 more sources

Role of myostatin in metabolism

Current Opinion in Clinical Nutrition & Metabolic Care, 2004
To review papers on myostatin published in 2003 and early 2004. Myostatin is a negative regulator of skeletal muscle mass produced in this tissue. Inactivating mutations of the myostatin gene or interaction of myostatin protein with follistatin and other inhibitory proteins induce a hypermuscular phenotype in cattle and mice; this is assumed to result ...
Nestor F, Gonzalez-Cadavid, Shalender, Bhasin   +1 more
openaire   +2 more sources